Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00919763 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis
A Phase 2 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT00919763 is a Phase 2 study that has completed, run by Galderma R&D. The registered enrollment target is 102 participants.
The verdict
NCT00919763, a Phase 2 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
This was a multi-center, randomized, double-blind, parallel group study. Efficacy Objectives: To evaluate the efficacy of CD2027 ointment 3 mcg/g applied twice daily over 4 weeks versus its vehicle in adult participants with at least moderate atopic dermatitis. Safety objective: To evaluate safety of CD2027 ointment 3 mcg/g when applied twice daily over 4 weeks versus its vehicle on 5 percent (%) - 20% involved Body Surface Area (BSA) (excluding Head/Neck) in adult participants with at least moderate atopic dermatitis.
Interventions
- DRUG CD2027 Ointment 3 mcg/g, twice daily
- DRUG Vehicle Ointment, twice daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2009-05-21 |
| Est. Completion | 2009-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00919763
The ClinicalTrials.gov registry entry for NCT00919763 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CD2027 Ointment 3 mcg/g, twice daily is the first listed.
NCT00919763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00919763 about?
NCT00919763 is a clinical study titled "Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis". This was a multi-center, randomized, double-blind, parallel group study. Efficacy Objectives: To evaluate the efficacy of CD2027 ointment 3 mcg/g applied twice daily over 4 weeks versus its vehicle in adult participants with at least moderate atopic dermatitis. Safety objective: To evaluate safety ...
What is the current status of trial NCT00919763?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2009-05-21. Estimated completion is 2009-10-01.
What interventions are being tested in trial NCT00919763?
The interventions under investigation include: CD2027 Ointment 3 mcg/g, twice daily (DRUG), Vehicle Ointment, twice daily (DRUG).
Who is sponsoring clinical trial NCT00919763?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.